Antidepressant Guide for Pain and PTSD in PI Cases

Amar Lunagaria — Co-Founder & Chief Pharmacist, LienScripts | March 4, 2026 | 11 min read

A comprehensive guide to antidepressants prescribed for chronic pain, PTSD, and mood disorders in personal injury -- SSRIs (sertraline, paroxetine), SNRIs (duloxetine, venlafaxine), TCAs (amitriptyline, nortriptyline), and atypical agents -- comparing dual indications, mechanisms, and documentation value.

Antidepressants are a broad class of medications that modulate serotonin, norepinephrine, and other neurotransmitter systems in the central nervous system. In personal injury cases, antidepressants serve dual clinical roles that make them uniquely valuable for documentation: they treat both the chronic pain syndromes that develop after traumatic injury and the mood disorders (depression, anxiety, PTSD) that are direct psychological consequences of the trauma.

• Antidepressants in PI cases serve dual purposes -- treating chronic neuropathic pain AND mood/psychological consequences of traumatic injury
• Three major subclasses are used: SSRIs (sertraline, paroxetine, fluoxetine, escitalopram), SNRIs (duloxetine, venlafaxine, milnacipran), and TCAs (amitriptyline, nortriptyline, doxepin)
• SNRIs like duloxetine have FDA-approved indications for both major depressive disorder and chronic pain conditions, making them the most commonly prescribed antidepressant subclass in PI
• The presence of any antidepressant in a PI pharmacy record documents that the injury produced consequences beyond physical pain, supporting general damages claims
• LienScripts documents antidepressant prescriptions through its pharmacy lien program, capturing both pain management and psychological injury treatment

Why Antidepressants Are Prescribed After Traumatic Injury

The connection between traumatic injury and antidepressant prescriptions is not incidental. Research consistently demonstrates that:

Chronic pain and depression share neurobiological pathways. Serotonin and norepinephrine are involved in both pain modulation (descending inhibitory pathways in the spinal cord) and mood regulation (limbic system). A traumatic injury that produces chronic pain simultaneously disrupts the neurotransmitter systems that regulate mood.

PTSD develops in a significant percentage of accident victims. Motor vehicle accident survivors develop PTSD at rates between 20-40%. PTSD involves hyperarousal, intrusive re-experiencing, avoidance behaviors, and emotional numbing -- all of which are treated pharmacologically with antidepressants.

Depression complicates injury recovery. Depressed patients have worse pain outcomes, lower medication adherence, reduced participation in rehabilitative therapies, and longer recovery timelines. Treating the depression is medically necessary for optimal injury recovery.

Comprehensive Comparison: All Antidepressants in PI Practice

When Physicians Prescribe Each Subclass

SNRIs for Dual Pain and Mood Treatment

Duloxetine is the most commonly prescribed antidepressant in PI cases because it has FDA-approved indications for both chronic musculoskeletal pain and major depressive disorder. When a treating physician prescribes duloxetine 60 mg daily, they are simultaneously addressing the chronic pain component of the injury and the depressive symptoms it has produced.

Venlafaxine is the preferred SNRI when PTSD is the dominant psychological presentation. At higher doses (150-225 mg), venlafaxine provides robust norepinephrine reuptake inhibition that is effective for both PTSD symptoms and the descending pain modulation pathway.

SSRIs for PTSD and Psychological Trauma

Sertraline and paroxetine are the only two SSRIs with FDA-approved PTSD indications. Their presence in a PI pharmacy record is direct pharmaceutical evidence that the treating physician -- or a psychiatrist -- diagnosed PTSD or significant psychological trauma resulting from the accident. This is powerful documentation for general damages because it proves the injury produced lasting psychological harm beyond physical symptoms.

TCAs for Neuropathic Pain

Amitriptyline and nortriptyline are older antidepressants that have well-established efficacy for neuropathic pain conditions. In PI cases, they are typically prescribed at lower doses than their antidepressant dosing (25-75 mg vs. 150-300 mg) specifically for nerve pain management. The TCA's presence in the record signals that the physician identified a neuropathic pain component to the injury.

Atypical Agents for Specific Presentations

Mirtazapine is prescribed when the injured patient presents with depression combined with significant appetite loss and sleep disruption. Its sedating and appetite-stimulating properties make it specifically useful for patients who are physically depleted from their injury. Bupropion is chosen for depression with prominent fatigue when the patient does not have a significant pain component, as it lacks the analgesic properties of SNRIs and TCAs.

Treatment Escalation Patterns and PI Documentation Value

Antidepressant escalation patterns provide detailed documentation of the injury's evolving psychological and pain impact:

• SNRI monotherapy to SNRI + SSRI augmentation -- Initial dual-purpose treatment insufficient; psychological symptoms require additional targeted therapy
• SSRI to SNRI -- Mood treatment expanded to include pain management; pain component worsening or newly identified
• SNRI to SNRI + TCA -- Pain management escalation; neuropathic component requires additional pharmacological targeting
• One SSRI to another SSRI -- Side effect management or inadequate response; physician actively managing psychological treatment
• Antidepressant dose escalation -- Standard titration to therapeutic range, or dose increase reflecting worsening symptoms at a previously effective dose

As Amar Lunagaria, PharmD, LienScripts' Chief Pharmacist with clinical experience in psychiatric pharmacy, explains, "Antidepressant prescriptions in PI cases are the single most underutilized piece of pharmaceutical evidence for general damages. When the pharmacy record shows duloxetine 60 mg for pain plus sertraline 100 mg for PTSD, the treating physicians have documented two distinct injury consequences -- chronic pain and psychological trauma -- with two distinct pharmacological interventions."

Defense Challenges and Rebuttals

"The patient had pre-existing depression before the accident"

Rebuttal: Even if the patient had a history of depression, the pharmacy record can establish aggravation. If the antidepressant dose was increased after the accident, or a new agent was added, this documents worsening of the pre-existing condition caused by the traumatic injury. Under the eggshell plaintiff doctrine, the defendant takes the plaintiff as they find them.

"Antidepressants are prescribed for minor mood changes, not real injury"

Rebuttal: The decision to prescribe an antidepressant -- particularly a controlled-access medication requiring ongoing physician monitoring -- reflects a clinical diagnosis of a condition meeting DSM-5 criteria. This is not a minor mood change; it is a diagnosable psychiatric condition that the physician determined requires pharmacological intervention.

"The PTSD could be caused by factors other than the accident"

Rebuttal: Temporal correlation is established by the pharmacy record. If no psychiatric medications appear before the accident date and sertraline or paroxetine prescriptions begin within weeks to months afterward, the causation timeline is documented. The treating physician's or psychiatrist's clinical judgment linked the PTSD to the traumatic event.

MERIT Documentation for Antidepressant Cases

LienScripts generates a MERIT (Medication Evaluation & Rationale for Injury Treatment) report for every case, providing pharmacist-signed documentation for demand packages. For cases involving antidepressants, the MERIT report documents the dual nature of treatment -- pain management and psychological injury -- alongside the complete pain medication timeline, creating a comprehensive picture that supports both special and general damages claims.